Efgartigimod (Vyvgart): The Antibody Fragment That Treats Autoimmune Disease by Deleting Your Own Antibodies (July 23, 2026)
Table of Contents
The receptor that keeps your antibodies alive
Antibodies are supposed to be disposable, but they last for weeks. The reason is a single receptor called FcRn, the neonatal Fc receptor. As cells constantly sip fluid from the bloodstream, any IgG antibody they take in would normally be broken down inside the cell. FcRn intercepts it first: it binds IgG in the acidic interior of the cell, carries it back to the surface, and releases it into the blood, rescuing it from destruction. This recycling loop is why IgG has such a long half-life - and why it is the workhorse of both natural immunity and antibody drugs. The catch is that FcRn does not check whether an antibody is helpful or harmful. In autoimmune diseases like myasthenia gravis, the antibodies attacking your own tissue get recycled just as faithfully as the ones fighting infection. Efgartigimod's whole idea is to sabotage that loop on purpose.
What efgartigimod actually is
Despite living in a 'peptide' catalog, efgartigimod is not a small synthetic peptide - it is an engineered fragment of a human IgG1 antibody. Specifically, it is the Fc portion, the exact tail of the antibody that binds FcRn, cut away from everything else. argenx took that fragment and applied its ABDEG technology (a set of mutations whose name stands for 'antibodies that enhance IgG degradation'), which cranks up its grip on FcRn. The result binds FcRn far more tightly than ordinary IgG, and - the crucial part - it keeps holding on even at the neutral pH of the cell surface, where a normal antibody would let go. In effect, efgartigimod is a decoy that jams the recycling receptor in the occupied position.
Block the recycling, lose the antibodies
When FcRn is occupied by the drug, your own circulating IgG can no longer catch a ride back to the bloodstream. Instead it goes where unrescued antibodies go: to the lysosome, to be degraded. Across a dosing cycle this drops total IgG by roughly 60 to 70 percent within a couple of weeks - and because pathogenic autoantibodies are just IgG, they fall along with everything else. What makes the approach elegant is its selectivity. Efgartigimod lowers IgG but leaves IgM, IgA, complement proteins, and albumin essentially untouched, because those do not depend on FcRn. That is a very different footprint from steroids or broad immunosuppressants, which blunt the whole immune system, and from plasma exchange, which physically strains antibodies out of the blood. And it is reversible: stop dosing and IgG climbs back, which is why the drug is given in cycles rather than continuously.
Myasthenia gravis: the first proof
The disease that carried efgartigimod to market was generalized myasthenia gravis (gMG), where antibodies against the acetylcholine receptor block the signal muscles need to contract, producing fluctuating weakness. In the Phase 3 ADAPT trial, about 68 percent of treated antibody-positive patients were responders on the MG-ADL daily-living scale, versus roughly 30 percent on placebo, with improvement showing up within one to two weeks of a cycle. That result made intravenous Vyvgart the first FcRn blocker ever approved, in December 2021. It was a category-defining moment: a new mechanism, validated in a disease where the villain - an IgG autoantibody - was already well understood.
From an IV drip to a 60-second shot, and into CIDP
argenx then attacked the two things patients dislike most: the infusion chair and the narrowness of the label. Vyvgart Hytrulo pairs efgartigimod with recombinant human hyaluronidase PH20, an enzyme that briefly loosens the tissue under the skin so a large dose can be pushed in as a subcutaneous injection lasting 30 to 90 seconds instead of an hour-long IV. That subcutaneous form was approved for gMG in 2023, and in June 2024 it became the first FcRn blocker approved for chronic inflammatory demyelinating polyneuropathy (CIDP) - a disease where autoantibodies attack peripheral nerves - on the strength of the ADHERE study, which used a randomized-withdrawal design and showed a sharply lower relapse risk in responders. By April 2025 a prefilled syringe let patients inject at home.
May 2026: the drug for everyone with gMG
The newest milestone is the reason efgartigimod is in the news again. About one in ten gMG patients are 'seronegative' - they have the disease but no detectable acetylcholine-receptor, MuSK, or LRP4 antibodies on standard tests - and they had been left out of most targeted therapies. The Phase 3 ADAPT SERON trial enrolled 119 such patients and showed a mean MG-ADL improvement of about 3.35 points at week 4, consistent across MuSK-positive, LRP4-positive, and triple-seronegative groups. On May 8, 2026 the FDA expanded the label to cover all serotypes, making efgartigimod the first and only gMG treatment approved regardless of antibody status. It is a notable point about the FcRn mechanism: because it lowers the whole IgG pool rather than targeting one specific antibody, it can help patients whose culprit antibody has not even been identified.
A platform, and its limits
Because the mechanism works anywhere pathogenic IgG drives disease, efgartigimod behaves less like a single-disease drug and more like a platform. argenx and others are testing it in primary immune thrombocytopenia, myositis, Sjogren's disease, bullous pemphigoid, and lupus nephritis, and it now anchors a competitive FcRn-blocker class alongside rozanolixizumab, nipocalimab, and batoclimab. The limits are the flip side of the mechanism. Lowering IgG by 60 to 70 percent raises infection risk - infections and headache were the most common adverse events, plus injection-site reactions for the subcutaneous form - and the long-term consequences of repeatedly stripping down the antibody pool are still being mapped. It also does nothing for diseases not driven by IgG. But as a demonstration that you can treat autoimmunity by editing a housekeeping receptor rather than carpet-bombing the immune system, efgartigimod has already earned its place in the story of modern biologics.
Ready to track your peptide research?
Open PepTracker ProPepTracker Pro Research Team
The PepTracker Pro Research Team is an editorial group of science writers, pharmacologists, and clinical researchers dedicated to making peptide science accessible. Every article is reviewed for accuracy against peer-reviewed sources and updated as new evidence emerges.
Citations
- [1] argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - argenx, May 2026 Source
- [2] Efgartigimod Gains FDA Approval as First Treatment for Seronegative Forms of Myasthenia Gravis (ADAPT SERON) - NeurologyLive Source
- [3] FDA Approves Efgartigimod as New Treatment for Chronic Inflammatory Demyelinating Polyneuropathy - NeurologyLive Source
- [4] Efgartigimod: A Novel FcRn Antagonist in the Treatment of Autoimmune Diseases - The Antibody Society Source
- [5] Efgartigimod alfa (identifiers, mechanism, indications) - DrugBank DB15270 Source
- [6] Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) FDA Approval History - Drugs.com Source
Related Articles
Zilucoplan (Zilbrysq): The Self-Injectable Peptide That Blocks Complement in Myasthenia Gravis (June 23, 2026)
Zilucoplan is a macrocyclic peptide that switches off the final step of the complement cascade. Unlike the IV antibodies that came before it, patients inject it under the skin once a day. Here is how it works and what the evidence shows.
Pegcetacoplan: The Cyclic Peptide That Tamed Complement C3 - and Just Became the First Drug for Two Rare Kidney Diseases (July 3, 2026)
Pegcetacoplan started as compstatin, a lab peptide that grabs complement C3. Engineered into a PEGylated cyclic-peptide dimer, it's now approved for PNH, geographic atrophy, and - since July 2025 - as the first treatment for the rare kidney diseases C3G and IC-MPGN. Here's how a peptide reached the market three times over.
Sotatercept (Winrevair): The Activin Trap That Made Pulmonary Arterial Hypertension a Treatable Disease, Not Just a Managed One (July 18, 2026)
Merck's sotatercept (Winrevair) is a fusion protein that traps activin A, activin B, myostatin and GDF-11 - and it changed what pulmonary arterial hypertension therapy can aim for. STELLAR delivered a 40.8-meter gain in 6-minute walk distance; ZENITH cut death, transplant and hospitalization by 76% in the sickest patients and led to an expanded FDA label on October 27, 2025. Here is how the broadest activin-axis drug compares with the selective antibodies chasing the same biology.